Separately, the Japanese firm has also sold its former US headquarters in Deerfield, IL for $115m to Ireland-based Horizon Therapeutics PLC.
The $825m deal with Hypera comprises what the Japanese firm considers to be non-core over-the-counter and prescription pharmaceutical products in...








